DCC-2812 – GCN2 Activator
Advanced/metastatic genitourinary cancers
About this program
DCC-2812 is a selective activator of general control nonderepressible 2 (GCN2) activator currently being studied as a monotherapy in advanced/metastatic renal cell carcinoma, urothelial carcinoma, and castration-resistant prostate cancer.
To learn more about this study, click here.